Cancer blood testDetecting cancer cells isn't always easy, especially when only a few tumor cells are mixed among many healthy ones. But Veridex, a Johnson & Johnson (JNJ) company, today announced a collaboration aimed at developing exactly such a blood test. With Massachusetts General Hospital and another J&J's unit, Ortho Biotech Oncology Research & Development, Veridex will focus on developing a next-generation blood test that would capture, count and characterize tumor cells found in patients' blood.

Circulating tumor cells (CTC) are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream, which could mean the cancer has spread further.

Right now, Veridex is the only company to have brought CTC technology to the U.S. market with its CellSearch in-vitro diagnostic test. But the procedure only counts tumor cells in the blood. While it can help with prognosis, it can't help analyze the cells to choose the best treatment. That's where the new technology would come in.

Replacing Painful and Invasive Biopsies?


The new technology to find circulating tumor cells could be used not only as a diagnostic tool to personalize care, Veridex says, but as a research tool as to improve the process of drug discovery and development. The technology could specifically isolate and explore the biology of rare cells at the protein, RNA and DNA levels, the company said.

If successful, the blood test could ultimately replace more invasive and painful ones such as biopsies. Further, doctors and patients could get a better idea on the progress of the cancer, replacing scans and other measures.

"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells," said Robert McCormack, Head of Technology Innovation and Strategy in a statement. "Harnessing the information contained in these cells. . .could enable tools to help select treatment and monitor how patients are responding."

Nicholas Dracopoli, VP of Biomarkers at Ortho Biotech, one of the project's collaborators, added: "The role of CTCs in drug discovery and development is growing as new technologies allow us to use CTCs for the first time as templates for novel DNA, RNA and protein biomarkers."

Increase your money and finance knowledge from home

Introduction to Preferred Shares

Learn the difference between preferred and common shares.

View Course »

Introduction to Value Investing

Are you the next Warren Buffett?

View Course »

Add a Comment

*0 / 3000 Character Maximum

3 Comments

Filter by:
Debbie Heeney

If you can find the tumor cells that are circulating in the blood stream,than you also can remove them.Kind of like a filtering process.When you go to dialises for your kidneys they clean your blood,right?

January 03 2011 at 2:44 PM Report abuse rate up rate down Reply
jcc4567

its all about profits...whatever is the most profitable to investors, gets the greenlight. Still doesn't mean a single hospital in the world will use it, but if made mainstream it sure looks to be better than current invasive practices used currently. Problem is, it may detect alot more cancer & therefore alot more people will be treated with a pretty flawed method of chemo/radiation. Its said that your average person develops cancer cells some 2000 times in their life & may or may not ever 'come down' with it...but if everyone was tested routinely, one thing is for sure, more people will be treated & with the current 10-30% success rate, this could mean alot more problems for alot of people

January 03 2011 at 1:59 PM Report abuse rate up rate down Reply
sts77

what about BOCX sounds like a better test. and theraputic patents on going.
i dont get it.

January 03 2011 at 12:14 PM Report abuse rate up rate down Reply